The Impact of Bupropion on Psychomotor Performance

PDF

Authors
  1. Paul, M.A.
  2. Gray, G.
  3. Kenny, G.
  4. Lange, M.
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN)
Abstract
The NDRI (noradrenalin-dopamine re-uptake inhibitor) bupropion SR (sustained-release) is marketed as Wellbutrin™ for treatment of depression or Zyban™ as a smoking cessation aid. There has been considerable interest in the possibility of returning aircrew to restricted flying duties once stabilized on bupropion SR after resolution of depression symptoms, or while taking bupripion SR for smoking cessation. This study was undertaken to determine whether bupropion SR affects psychomotor performance. There were 24 subjects (18 men and 6 women) who were assess for psychomotor performance during placebo and bupropion SR treatment, in a double-blind cross-over in counter-balanced order. Each treatment arm lasted 5 wk. The daily bupropion SR dose was 150 mg during week 1, and 300 mg during weeks 2 to 5. Subjects completed a drug side-effct questionnaire and were tested on two psychomotor test batteries once per week during each of the placebo and drug arms. TRUNCATED
Keywords
Aircrew;Antidepressants;Psychomotor performance;Side effects
Report Number
DCIEM-SL-2001-128 — Reprint
Date of publication
01 Nov 2002
Number of Pages
8
Reprinted from
Aviation, Space and Environmental Medicine, vol 73, no 11, 2002, p 1094-1099
DSTKIM No
CA021782
CANDIS No
518507
Format(s):
Hardcopy

Permanent link

Document 1 of 1

Date modified: